Evidence map›Paper›PMID 31048084›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2019

Listeria innocua Dps as a nanoplatform for bioluminescence based photodynamic therapy utilizing Gaussia princeps luciferase and zinc protoporphyrin IX.

Ali W Al-Ani, Lei Zhang, Lenny Ferreira, Lyudmila Turyanska, Tracey D Bradshaw, Neil R Thomas

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Bioluminescent Systems for Theranostic Applications.International journal of molecular sciences · 2024
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Recent Advances in Self-Exciting Photodynamic Therapy.Frontiers in bioengineering and biotechnology · 2020
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ali W Al-AniCentre for Biomolecular Sciences, School of Chemistry, The University of Nottingham, Nottingham, UK.
Lei ZhangCentre for Biomolecular Sciences, School of Chemistry, The University of Nottingham, Nottingham, UK.
Lenny FerreiraCentre for Biomolecular Sciences, School of Chemistry, The University of Nottingham, Nottingham, UK.
Lyudmila TuryanskaSchool of Physics & Astronomy, The University of Nottingham, University Park, Nottingham, UK; and School of Chemistry, University of Lincoln, UK.
Tracey D BradshawCentre for Biomolecular Sciences, School of Pharmacy, The University of Nottingham, University Park, Nottingham, UK.
Neil R ThomasCentre for Biomolecular Sciences, School of Chemistry, The University of Nottingham, Nottingham, UK. Electronic address: neil.thomas@nottingham.ac.uk.
University of Nottingham · GBUniversity of Lincoln · GB

Funding

Biotechnology and Biological Sciences Research Council BB/M008770/1Medical Research Council G0801741National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/L001861/1
6 · The paper itself

Abstract

Listeria innocua DNA binding protein from starved cells (LiDps) belongs to the ferritin family and provides a promising self-assembling spherical 12-mer protein scaffold for the generation of functional nanomaterials. We report the creation of a Gaussia princeps luciferase (Gluc)-LiDps fusion protein, with chemical conjugation of Zinc (II)-protoporphyrin IX (ZnPP) to lysine residues on the fusion protein (giving Gluc-LiDps-ZnPP). The Gluc-LiDps-ZnPP conjugate is shown to generate reactive oxygen species (ROS) via Bioluminescence Resonance Energy Transfer (BRET) between the Gluc (470-490 nm) and ZnPP. In vitro, Gluc-LiDps-ZnPP is efficiently taken up by tumorigenic cells (SKBR3 and MDA-MB-231 breast cancer cells). In the presence of coelenterazine, this construct inhibits the proliferation of SKBR3 due to elevated ROS levels. Following exposure to Gluc-LiDps-ZnPP, migration of surviving SKBR3 cells is significantly suppressed. These results demonstrate the potential of the Gluc-LiDps-ZnPP conjugate as a platform for future development of an anticancer photodynamic therapy agent.

Indexed as

Luminescent MeasurementsPhotochemotherapyAnimalsCell Line, TumorCopepodaDNA-Binding ProteinsHumansListeriaLuciferasesNanoparticlesProtoporphyrinsReactive Oxygen SpeciesWound HealingDNA-Binding ProteinsLuciferasesProtoporphyrinsReactive Oxygen Specieszinc protoporphyrinBioluminescence resonance energy transferGaussia princeps luciferaseListeria innocua DNA binding proteinPhotodynamic therapyZinc (II) protoporphyrin IX

Identifiers

PMID31048084
PMCPMC6712498
OpenAlexW2943552627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.